GleamWall
中文EN

CLDX Celldex Therapeutics, Inc.

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 744218 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-93.9%
TTM net income YoY-37.6%
TTM EPS YoY-26.9%
Revenue 3-yr CAGR-66.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-211,684.8%
Net margin-195,608.9%
FCF margin-164,391.8%
EBITDA margin-209,321.5%

Returns

ROE-49.5%
ROA-45.1%
ROIC (approx.)-44.6%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets10.0%
Debt / equity0.00x
Current ratio10.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-8.3%
Payout ratio—
Capex / revenue4,915.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.54M$7.02M
Cost of revenue$200,000$200,000
Gross profit$1.34M$6.82M
R&D expense$245.07M$163.55M
SG&A expense$43.84M$38.55M
Operating income-$287.37M-$195.08M
Pretax income-$258.76M-$157.86M
Income tax$0$0
Net income-$258.76M-$157.86M
EBITDA-$283.99M-$191.90M
EPS (basic)-3.90-2.45
EPS (diluted)-3.90-2.45
Weighted avg. shares (diluted)66.42M64.39M
Balance sheet
Cash & equivalents$28.87M$28.36M
Short-term investments$489.70M$696.92M
Current assets$534.66M$747.16M
PP&E, net$5.33M$4.35M
Intangibles$27.19M$27.19M
Total assets$582.98M$792.34M
Current liabilities$50.99M$39.50M
Total liabilities$55.82M$45.34M
Shareholders' equity$527.16M$747.00M
Shares outstanding66.55M66.37M
Cash flow statement
Operating cash flow-$210.94M-$157.78M
Capital expenditure$2.71M$1.92M
Free cash flow-$213.66M-$159.70M
Investing cash flow$209.07M-$290.13M
Financing cash flow$2.39M$441.45M
Depreciation & amortization$3.38M$3.18M
Stock-based compensation$36.22M$34.24M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.